Kisqali (200 MG Dose) and Tezacaftor and Ivacaftor
Determining the interaction of Kisqali (200 MG Dose) and Tezacaftor and Ivacaftor and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Ribociclib may significantly increase the blood levels of ivacaftor from certain formulations. This may increase the risk and/or severity of serious side effects such as liver damage. A dosage adjustment may be required. Talk to your doctor if you have any questions or concerns, or if you do not know whether your dosage has already been adjusted. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivacaftor, which is primarily metabolized by the isoenzyme. In study subjects, ivacaftor peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 2.5- and 3.0-fold when it was administered concomitantly with fluconazole, a moderate CYP450 3A4 inhibitor. When lumacaftor/ivacaftor was coadministered with ciprofloxacin, another moderate CYP450 3A4 inhibitor, lumacaftor Cmax and AUC decreased by 12% and 14%, respectively, while ivacaftor Cmax and AUC increased by 29% each. These changes are not considered clinically significant. Physiologically based pharmacokinetic (PBPK) simulations suggest that coadministration with moderate CYP450 3A4 inhibitors may increase elexacaftor AUC by 1.9- to 2.3-fold and tezacaftor AUC by approximately 2.1-fold.
MANAGEMENT: Please consult manufacturer's product labeling for complete dosing information.
For ivacaftor - The dosage for patients 6 years or older should be reduced to 150 mg once daily when used with moderate CYP450 3A4 inhibitors (2 to
- "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
- "Product Information. Symdeko 4-Week (ivacaftor-tezacaftor)." Vertex Pharmaceuticals, Cambridge, MA.
Generic Name: ribociclib
Brand name: Kisqali
Synonyms: Kisqali
Generic Name: ivacaftor / tezacaftor
Brand name: Symdeko, Symdeko 4-Week
Synonyms: Ivacaftor and tezacaftor
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Kisqali (200 MG Dose)-Tezacaftor/ivacaftor and ivacaftor
- Kisqali (200 MG Dose)-TGQ 30PSE/3BRM/15DM
- Kisqali (200 MG Dose)-TGQ 7.5PEH/4BRM/15DM
- Kisqali (200 MG Dose)-TGT First Aid Antibiotic
- Kisqali (200 MG Dose)-TGT First Aid Cleansing
- Kisqali (200 MG Dose)-TH Antibiotic + Pain Relief
- Tezacaftor and Ivacaftor-Kisqali (400 MG Dose)
- Tezacaftor and Ivacaftor-Kisqali (600 MG Dose)
- Tezacaftor and Ivacaftor-Kisqali Femara Co-Pack
- Tezacaftor and Ivacaftor-Kisqali Femara Co-Pack 200 mg-2.5 mg Dose
- Tezacaftor and Ivacaftor-Kisqali Femara Co-Pack 400 mg-2.5 mg Dose
- Tezacaftor and Ivacaftor-Kisqali Femara Co-Pack 600 mg-2.5 mg Dose